| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 107 | 2023 | 178 | 19.890 |
Why?
|
| Atrial Fibrillation | 107 | 2023 | 164 | 19.540 |
Why?
|
| Stroke | 92 | 2023 | 306 | 13.120 |
Why?
|
| Heart Failure | 68 | 2023 | 391 | 12.690 |
Why?
|
| Kidney Failure, Chronic | 51 | 2023 | 148 | 9.900 |
Why?
|
| Anticoagulants | 65 | 2023 | 122 | 8.710 |
Why?
|
| Myocardial Infarction | 54 | 2022 | 251 | 8.040 |
Why?
|
| Acute Kidney Injury | 28 | 2024 | 43 | 8.000 |
Why?
|
| Aged | 295 | 2023 | 6258 | 7.940 |
Why?
|
| Humans | 467 | 2024 | 18058 | 7.660 |
Why?
|
| Male | 326 | 2024 | 10173 | 6.980 |
Why?
|
| Female | 338 | 2024 | 12838 | 6.580 |
Why?
|
| Cardiovascular Diseases | 54 | 2023 | 613 | 6.540 |
Why?
|
| Warfarin | 39 | 2023 | 74 | 6.490 |
Why?
|
| Middle Aged | 261 | 2024 | 8073 | 6.150 |
Why?
|
| Risk Factors | 181 | 2023 | 3394 | 6.080 |
Why?
|
| Glomerular Filtration Rate | 62 | 2023 | 156 | 5.520 |
Why?
|
| Coronary Artery Disease | 28 | 2022 | 132 | 5.420 |
Why?
|
| Aged, 80 and over | 108 | 2023 | 1956 | 5.350 |
Why?
|
| Hospitalization | 49 | 2023 | 813 | 5.230 |
Why?
|
| Risk Assessment | 71 | 2023 | 1137 | 5.090 |
Why?
|
| Coronary Disease | 22 | 2019 | 182 | 4.360 |
Why?
|
| Coronary Artery Bypass | 11 | 2016 | 26 | 4.080 |
Why?
|
| Venous Thromboembolism | 10 | 2023 | 50 | 4.070 |
Why?
|
| Cohort Studies | 103 | 2023 | 2631 | 3.900 |
Why?
|
| Retrospective Studies | 84 | 2023 | 2498 | 3.860 |
Why?
|
| Heart Diseases | 24 | 2019 | 78 | 3.710 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 15 | 2022 | 177 | 3.690 |
Why?
|
| Adult | 141 | 2024 | 7696 | 3.680 |
Why?
|
| Kidney | 16 | 2022 | 53 | 3.680 |
Why?
|
| Registries | 41 | 2022 | 486 | 3.620 |
Why?
|
| Treatment Outcome | 59 | 2022 | 1259 | 3.420 |
Why?
|
| American Heart Association | 22 | 2022 | 49 | 3.350 |
Why?
|
| United States | 129 | 2024 | 4119 | 3.320 |
Why?
|
| Percutaneous Coronary Intervention | 10 | 2016 | 22 | 3.300 |
Why?
|
| Incidence | 67 | 2023 | 1297 | 3.250 |
Why?
|
| California | 66 | 2024 | 2327 | 3.240 |
Why?
|
| Ventricular Function, Left | 18 | 2023 | 47 | 3.160 |
Why?
|
| Hypertension | 18 | 2023 | 489 | 3.130 |
Why?
|
| Disease Progression | 36 | 2023 | 255 | 3.050 |
Why?
|
| Atherosclerosis | 12 | 2023 | 51 | 2.760 |
Why?
|
| Time Factors | 52 | 2024 | 1114 | 2.670 |
Why?
|
| Adrenergic beta-Antagonists | 12 | 2017 | 44 | 2.650 |
Why?
|
| Follow-Up Studies | 64 | 2021 | 1255 | 2.520 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 8 | 2022 | 94 | 2.510 |
Why?
|
| Thromboembolism | 15 | 2023 | 33 | 2.490 |
Why?
|
| Prognosis | 52 | 2023 | 619 | 2.470 |
Why?
|
| Renal Dialysis | 18 | 2020 | 57 | 2.430 |
Why?
|
| Creatinine | 20 | 2023 | 67 | 2.410 |
Why?
|
| Prospective Studies | 76 | 2023 | 1294 | 2.410 |
Why?
|
| Proteinuria | 11 | 2021 | 23 | 2.260 |
Why?
|
| Angiotensin Receptor Antagonists | 4 | 2022 | 54 | 2.170 |
Why?
|
| Delivery of Health Care, Integrated | 11 | 2023 | 552 | 2.150 |
Why?
|
| Biomarkers | 40 | 2024 | 306 | 2.060 |
Why?
|
| Stroke Volume | 15 | 2023 | 95 | 2.050 |
Why?
|
| Hemorrhage | 26 | 2023 | 63 | 2.050 |
Why?
|
| Kidney Diseases | 11 | 2011 | 53 | 2.040 |
Why?
|
| Primary Prevention | 9 | 2018 | 77 | 2.010 |
Why?
|
| Defibrillators, Implantable | 8 | 2018 | 33 | 1.920 |
Why?
|
| Emergency Service, Hospital | 10 | 2023 | 357 | 1.920 |
Why?
|
| Patient Discharge | 10 | 2022 | 150 | 1.900 |
Why?
|
| Proportional Hazards Models | 39 | 2021 | 745 | 1.860 |
Why?
|
| Cause of Death | 20 | 2021 | 181 | 1.840 |
Why?
|
| Biomedical Research | 8 | 2020 | 89 | 1.810 |
Why?
|
| Continental Population Groups | 13 | 2021 | 317 | 1.730 |
Why?
|
| Platelet Aggregation Inhibitors | 9 | 2021 | 24 | 1.730 |
Why?
|
| Patient Readmission | 9 | 2020 | 161 | 1.710 |
Why?
|
| Death, Sudden, Cardiac | 8 | 2018 | 36 | 1.670 |
Why?
|
| Brain Ischemia | 13 | 2016 | 37 | 1.650 |
Why?
|
| Comorbidity | 32 | 2023 | 618 | 1.630 |
Why?
|
| Cardiology | 7 | 2022 | 29 | 1.610 |
Why?
|
| Hyperkalemia | 2 | 2022 | 21 | 1.590 |
Why?
|
| Blood Pressure | 18 | 2023 | 280 | 1.550 |
Why?
|
| Age Factors | 34 | 2020 | 945 | 1.520 |
Why?
|
| Ventricular Dysfunction, Left | 8 | 2017 | 21 | 1.500 |
Why?
|
| Severity of Illness Index | 19 | 2020 | 454 | 1.500 |
Why?
|
| Research Report | 7 | 2020 | 22 | 1.450 |
Why?
|
| Renin-Angiotensin System | 2 | 2020 | 18 | 1.450 |
Why?
|
| Mortality | 13 | 2021 | 121 | 1.440 |
Why?
|
| Pulmonary Embolism | 4 | 2020 | 43 | 1.390 |
Why?
|
| Anti-Arrhythmia Agents | 4 | 2019 | 12 | 1.360 |
Why?
|
| Cystatin C | 7 | 2023 | 15 | 1.350 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 8 | 2023 | 20 | 1.350 |
Why?
|
| Outpatients | 4 | 2023 | 113 | 1.330 |
Why?
|
| Polymorphism, Single Nucleotide | 18 | 2015 | 407 | 1.310 |
Why?
|
| Anemia | 8 | 2020 | 32 | 1.260 |
Why?
|
| Prevalence | 36 | 2018 | 892 | 1.230 |
Why?
|
| Atrial Flutter | 7 | 2023 | 15 | 1.200 |
Why?
|
| Morbidity | 5 | 2020 | 62 | 1.200 |
Why?
|
| Diabetes Mellitus | 11 | 2019 | 526 | 1.190 |
Why?
|
| Fibrinolytic Agents | 14 | 2016 | 44 | 1.180 |
Why?
|
| Young Adult | 37 | 2020 | 2479 | 1.180 |
Why?
|
| International Normalized Ratio | 14 | 2022 | 22 | 1.180 |
Why?
|
| Catheter Ablation | 4 | 2019 | 11 | 1.170 |
Why?
|
| Survival Rate | 24 | 2019 | 266 | 1.140 |
Why?
|
| Electric Countershock | 7 | 2017 | 16 | 1.140 |
Why?
|
| Troponin I | 3 | 2016 | 8 | 1.120 |
Why?
|
| Cross-Sectional Studies | 41 | 2022 | 1309 | 1.120 |
Why?
|
| Predictive Value of Tests | 24 | 2020 | 350 | 1.110 |
Why?
|
| Digoxin | 3 | 2015 | 12 | 1.090 |
Why?
|
| Algorithms | 8 | 2021 | 235 | 1.080 |
Why?
|
| Multivariate Analysis | 23 | 2019 | 595 | 1.080 |
Why?
|
| Vitamin K | 10 | 2022 | 15 | 1.030 |
Why?
|
| Angioplasty, Balloon, Coronary | 3 | 2014 | 12 | 1.030 |
Why?
|
| Multiple Chronic Conditions | 2 | 2023 | 25 | 1.020 |
Why?
|
| Venous Thrombosis | 3 | 2020 | 20 | 1.020 |
Why?
|
| Odds Ratio | 20 | 2016 | 692 | 1.010 |
Why?
|
| Medication Adherence | 3 | 2020 | 255 | 0.990 |
Why?
|
| Cardiomyopathies | 3 | 2015 | 8 | 0.980 |
Why?
|
| Potassium | 2 | 2022 | 20 | 0.970 |
Why?
|
| Cognition Disorders | 6 | 2017 | 31 | 0.970 |
Why?
|
| Chronic Disease | 14 | 2023 | 462 | 0.960 |
Why?
|
| Outcome Assessment (Health Care) | 9 | 2018 | 248 | 0.960 |
Why?
|
| Drug-Eluting Stents | 4 | 2014 | 8 | 0.950 |
Why?
|
| Hispanic Americans | 12 | 2016 | 431 | 0.940 |
Why?
|
| Ticlopidine | 9 | 2016 | 16 | 0.940 |
Why?
|
| Heart Failure, Systolic | 2 | 2013 | 4 | 0.930 |
Why?
|
| Peripheral Arterial Disease | 6 | 2021 | 13 | 0.930 |
Why?
|
| Disease Management | 6 | 2020 | 143 | 0.930 |
Why?
|
| Secondary Prevention | 3 | 2020 | 51 | 0.910 |
Why?
|
| Dabigatran | 6 | 2018 | 8 | 0.900 |
Why?
|
| Hemoglobins | 6 | 2020 | 38 | 0.890 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2022 | 2 | 0.880 |
Why?
|
| Clinical Trials as Topic | 10 | 2016 | 123 | 0.880 |
Why?
|
| Aortic Valve Stenosis | 1 | 2022 | 3 | 0.880 |
Why?
|
| Adolescent | 25 | 2022 | 3714 | 0.870 |
Why?
|
| European Continental Ancestry Group | 16 | 2017 | 559 | 0.860 |
Why?
|
| Office Visits | 2 | 2020 | 85 | 0.850 |
Why?
|
| Forecasting | 2 | 2021 | 77 | 0.840 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2013 | 28 | 0.830 |
Why?
|
| Survival Analysis | 12 | 2019 | 225 | 0.830 |
Why?
|
| Quality of Life | 15 | 2024 | 509 | 0.830 |
Why?
|
| African Americans | 12 | 2022 | 485 | 0.830 |
Why?
|
| Fibroblast Growth Factors | 6 | 2019 | 11 | 0.820 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2021 | 1 | 0.820 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2021 | 1 | 0.820 |
Why?
|
| Telephone | 2 | 2020 | 175 | 0.820 |
Why?
|
| Nephrotic Syndrome | 1 | 2021 | 6 | 0.810 |
Why?
|
| Chi-Square Distribution | 14 | 2015 | 160 | 0.800 |
Why?
|
| Dementia | 2 | 2023 | 103 | 0.800 |
Why?
|
| Hypertrophy, Left Ventricular | 9 | 2017 | 15 | 0.800 |
Why?
|
| Propensity Score | 7 | 2019 | 90 | 0.790 |
Why?
|
| Medicare | 8 | 2022 | 206 | 0.790 |
Why?
|
| Education | 2 | 2020 | 18 | 0.780 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2021 | 9 | 0.770 |
Why?
|
| Drug Monitoring | 2 | 2020 | 26 | 0.770 |
Why?
|
| Aftercare | 2 | 2020 | 49 | 0.770 |
Why?
|
| Natural Language Processing | 1 | 2021 | 53 | 0.770 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2018 | 31 | 0.760 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2019 | 127 | 0.760 |
Why?
|
| Genome-Wide Association Study | 9 | 2023 | 248 | 0.760 |
Why?
|
| Mobility Limitation | 1 | 2020 | 17 | 0.750 |
Why?
|
| Independent Living | 1 | 2020 | 22 | 0.740 |
Why?
|
| Angina Pectoris | 4 | 2007 | 16 | 0.740 |
Why?
|
| Myocardial Revascularization | 5 | 2019 | 12 | 0.740 |
Why?
|
| Troponin T | 8 | 2022 | 10 | 0.730 |
Why?
|
| Sex Factors | 17 | 2021 | 634 | 0.730 |
Why?
|
| Aspirin | 11 | 2016 | 67 | 0.730 |
Why?
|
| Dopamine Agonists | 1 | 2020 | 3 | 0.730 |
Why?
|
| Heart Rate | 6 | 2015 | 38 | 0.730 |
Why?
|
| Hyperprolactinemia | 1 | 2020 | 3 | 0.730 |
Why?
|
| Logistic Models | 20 | 2016 | 953 | 0.730 |
Why?
|
| Data Accuracy | 1 | 2020 | 25 | 0.730 |
Why?
|
| Case-Control Studies | 20 | 2016 | 1164 | 0.720 |
Why?
|
| Inpatients | 3 | 2017 | 79 | 0.720 |
Why?
|
| Heart Valve Diseases | 1 | 2020 | 19 | 0.720 |
Why?
|
| Neoplasms | 7 | 2019 | 464 | 0.720 |
Why?
|
| Intracranial Hemorrhages | 7 | 2012 | 16 | 0.720 |
Why?
|
| Aging | 4 | 2019 | 159 | 0.710 |
Why?
|
| Longitudinal Studies | 15 | 2021 | 705 | 0.710 |
Why?
|
| Databases, Factual | 7 | 2019 | 330 | 0.700 |
Why?
|
| Renal Insufficiency | 2 | 2023 | 13 | 0.700 |
Why?
|
| Inflammation | 5 | 2024 | 61 | 0.700 |
Why?
|
| Practice Patterns, Physicians' | 7 | 2017 | 351 | 0.690 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 50 | 0.680 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 57 | 0.680 |
Why?
|
| Lung Diseases | 2 | 2017 | 32 | 0.680 |
Why?
|
| Cardiovascular Agents | 3 | 2020 | 19 | 0.680 |
Why?
|
| Electrocardiography | 14 | 2022 | 42 | 0.680 |
Why?
|
| Research Design | 8 | 2012 | 393 | 0.660 |
Why?
|
| Antithrombins | 2 | 2017 | 4 | 0.650 |
Why?
|
| Pandemics | 2 | 2022 | 293 | 0.650 |
Why?
|
| Patient Selection | 11 | 2014 | 194 | 0.640 |
Why?
|
| Kidney Transplantation | 4 | 2014 | 27 | 0.640 |
Why?
|
| Electronic Health Records | 5 | 2020 | 734 | 0.630 |
Why?
|
| Sex Characteristics | 4 | 2015 | 68 | 0.630 |
Why?
|
| Body Mass Index | 9 | 2015 | 961 | 0.630 |
Why?
|
| Postoperative Hemorrhage | 2 | 2015 | 8 | 0.610 |
Why?
|
| Kidney Function Tests | 8 | 2022 | 22 | 0.610 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2021 | 397 | 0.610 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 2 | 2016 | 8 | 0.600 |
Why?
|
| Obesity | 6 | 2015 | 839 | 0.600 |
Why?
|
| Quality Indicators, Health Care | 3 | 2017 | 197 | 0.600 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2015 | 407 | 0.600 |
Why?
|
| Population Surveillance | 5 | 2013 | 270 | 0.580 |
Why?
|
| Age Distribution | 11 | 2019 | 257 | 0.580 |
Why?
|
| Cardiotonic Agents | 2 | 2013 | 13 | 0.570 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2016 | 2 | 0.570 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2016 | 4 | 0.570 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2016 | 5 | 0.570 |
Why?
|
| Factor Xa Inhibitors | 4 | 2020 | 10 | 0.560 |
Why?
|
| Bradycardia | 1 | 2016 | 1 | 0.550 |
Why?
|
| Sinus Arrest, Cardiac | 1 | 2016 | 1 | 0.550 |
Why?
|
| Atrioventricular Block | 1 | 2016 | 1 | 0.550 |
Why?
|
| Tachycardia, Ventricular | 1 | 2016 | 6 | 0.550 |
Why?
|
| Data Collection | 7 | 2020 | 276 | 0.550 |
Why?
|
| African Continental Ancestry Group | 7 | 2021 | 165 | 0.540 |
Why?
|
| Surveys and Questionnaires | 12 | 2020 | 1346 | 0.540 |
Why?
|
| Peptide Fragments | 6 | 2022 | 28 | 0.540 |
Why?
|
| Natriuretic Peptide, Brain | 6 | 2022 | 27 | 0.540 |
Why?
|
| Overweight | 3 | 2010 | 272 | 0.530 |
Why?
|
| Health Maintenance Organizations | 11 | 2017 | 481 | 0.530 |
Why?
|
| Evidence-Based Medicine | 6 | 2016 | 195 | 0.520 |
Why?
|
| Calcinosis | 7 | 2012 | 40 | 0.510 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2015 | 12 | 0.510 |
Why?
|
| Stents | 1 | 2014 | 10 | 0.500 |
Why?
|
| Diphosphonates | 3 | 2011 | 64 | 0.500 |
Why?
|
| Vascular Calcification | 3 | 2022 | 9 | 0.500 |
Why?
|
| Heart Function Tests | 1 | 2014 | 2 | 0.490 |
Why?
|
| Administration, Oral | 13 | 2022 | 81 | 0.480 |
Why?
|
| Delivery of Health Care | 3 | 2020 | 445 | 0.470 |
Why?
|
| Primary Health Care | 1 | 2020 | 843 | 0.470 |
Why?
|
| Spironolactone | 1 | 2013 | 9 | 0.470 |
Why?
|
| Practice Guidelines as Topic | 5 | 2017 | 324 | 0.460 |
Why?
|
| Birth Rate | 1 | 2013 | 6 | 0.450 |
Why?
|
| Coronary Vessels | 5 | 2022 | 15 | 0.450 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2023 | 328 | 0.450 |
Why?
|
| Recovery of Function | 4 | 2020 | 28 | 0.440 |
Why?
|
| Multimorbidity | 2 | 2023 | 13 | 0.440 |
Why?
|
| Child, Preschool | 8 | 2021 | 1428 | 0.440 |
Why?
|
| Sex Distribution | 10 | 2019 | 192 | 0.440 |
Why?
|
| Likelihood Functions | 1 | 2012 | 49 | 0.430 |
Why?
|
| Monitoring, Ambulatory | 1 | 2012 | 17 | 0.430 |
Why?
|
| Ethnic Groups | 7 | 2021 | 504 | 0.430 |
Why?
|
| Interleukin-6 | 4 | 2022 | 25 | 0.430 |
Why?
|
| Diabetic Retinopathy | 3 | 2020 | 19 | 0.420 |
Why?
|
| Infant | 5 | 2023 | 1212 | 0.420 |
Why?
|
| Acute Disease | 5 | 2019 | 138 | 0.420 |
Why?
|
| Quality Improvement | 2 | 2013 | 205 | 0.420 |
Why?
|
| Cholesterol, LDL | 5 | 2016 | 124 | 0.420 |
Why?
|
| Asian Americans | 5 | 2011 | 184 | 0.410 |
Why?
|
| Motor Activity | 6 | 2013 | 208 | 0.410 |
Why?
|
| Sensitivity and Specificity | 12 | 2015 | 318 | 0.410 |
Why?
|
| Angina, Stable | 1 | 2011 | 4 | 0.410 |
Why?
|
| Blood Pressure Determination | 6 | 2023 | 56 | 0.400 |
Why?
|
| Recurrence | 4 | 2020 | 186 | 0.400 |
Why?
|
| Heart Ventricles | 4 | 2017 | 17 | 0.400 |
Why?
|
| Puerperal Disorders | 1 | 2011 | 9 | 0.400 |
Why?
|
| Coronary Restenosis | 1 | 2011 | 1 | 0.400 |
Why?
|
| Mouth Diseases | 1 | 2011 | 4 | 0.400 |
Why?
|
| Antihypertensive Agents | 4 | 2016 | 170 | 0.390 |
Why?
|
| Drug Therapy, Combination | 7 | 2019 | 118 | 0.390 |
Why?
|
| Heart | 3 | 2023 | 12 | 0.390 |
Why?
|
| Oral Health | 1 | 2011 | 20 | 0.390 |
Why?
|
| Outcome and Process Assessment (Health Care) | 6 | 2017 | 106 | 0.390 |
Why?
|
| Vascular Diseases | 1 | 2010 | 5 | 0.380 |
Why?
|
| Erythropoietin | 3 | 2007 | 3 | 0.380 |
Why?
|
| Community Health Services | 2 | 2008 | 85 | 0.380 |
Why?
|
| Blood Coagulation Factors | 3 | 2022 | 10 | 0.370 |
Why?
|
| Asian Continental Ancestry Group | 4 | 2012 | 92 | 0.370 |
Why?
|
| Risk | 11 | 2016 | 552 | 0.370 |
Why?
|
| Cognition | 2 | 2024 | 80 | 0.370 |
Why?
|
| Patient Compliance | 3 | 2020 | 303 | 0.370 |
Why?
|
| Osteoporosis | 1 | 2011 | 87 | 0.370 |
Why?
|
| Child | 8 | 2021 | 2519 | 0.360 |
Why?
|
| Quality of Health Care | 6 | 2013 | 346 | 0.360 |
Why?
|
| Graft Rejection | 1 | 2009 | 4 | 0.360 |
Why?
|
| Health Literacy | 2 | 2022 | 45 | 0.350 |
Why?
|
| Guideline Adherence | 3 | 2017 | 160 | 0.350 |
Why?
|
| Confidence Intervals | 7 | 2014 | 249 | 0.340 |
Why?
|
| Mental Disorders | 4 | 2015 | 290 | 0.340 |
Why?
|
| Nocturia | 1 | 2009 | 5 | 0.340 |
Why?
|
| Uric Acid | 1 | 2009 | 12 | 0.340 |
Why?
|
| Reproducibility of Results | 14 | 2021 | 394 | 0.340 |
Why?
|
| Diuretics | 2 | 2022 | 18 | 0.330 |
Why?
|
| Data Interpretation, Statistical | 5 | 2016 | 79 | 0.330 |
Why?
|
| Information Services | 1 | 2008 | 18 | 0.330 |
Why?
|
| Metabolic Syndrome | 5 | 2015 | 80 | 0.330 |
Why?
|
| Communicable Diseases | 1 | 2008 | 14 | 0.320 |
Why?
|
| Hospital Mortality | 6 | 2009 | 150 | 0.320 |
Why?
|
| Oligosaccharides | 1 | 2008 | 2 | 0.320 |
Why?
|
| Decision Support Techniques | 4 | 2020 | 92 | 0.310 |
Why?
|
| C-Reactive Protein | 5 | 2017 | 57 | 0.310 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 4 | 0.310 |
Why?
|
| Carbazoles | 1 | 2007 | 2 | 0.300 |
Why?
|
| Tartrates | 1 | 2007 | 2 | 0.300 |
Why?
|
| Propanolamines | 1 | 2007 | 3 | 0.300 |
Why?
|
| Metoprolol | 1 | 2007 | 6 | 0.300 |
Why?
|
| Atenolol | 1 | 2007 | 8 | 0.300 |
Why?
|
| Sepsis | 2 | 2023 | 71 | 0.300 |
Why?
|
| Bundle-Branch Block | 4 | 2000 | 5 | 0.300 |
Why?
|
| Adiposity | 2 | 2015 | 66 | 0.300 |
Why?
|
| Anti-Asthmatic Agents | 3 | 2007 | 67 | 0.300 |
Why?
|
| Vascular Surgical Procedures | 3 | 2015 | 4 | 0.300 |
Why?
|
| Hematinics | 1 | 2007 | 3 | 0.300 |
Why?
|
| Cardiac Resynchronization Therapy | 3 | 2017 | 4 | 0.300 |
Why?
|
| Membrane Proteins | 2 | 2022 | 40 | 0.290 |
Why?
|
| Renal Replacement Therapy | 2 | 2023 | 7 | 0.290 |
Why?
|
| Abdomen | 1 | 2006 | 20 | 0.290 |
Why?
|
| Heart Conduction System | 2 | 2018 | 4 | 0.280 |
Why?
|
| Genotype | 9 | 2022 | 251 | 0.280 |
Why?
|
| Growth Differentiation Factor 15 | 3 | 2022 | 4 | 0.280 |
Why?
|
| Vascular Stiffness | 2 | 2017 | 4 | 0.270 |
Why?
|
| Thrombophilia | 2 | 2015 | 3 | 0.270 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2006 | 19 | 0.270 |
Why?
|
| Echocardiography | 5 | 2023 | 30 | 0.270 |
Why?
|
| Dyslipidemias | 3 | 2015 | 63 | 0.270 |
Why?
|
| Quantitative Trait Loci | 3 | 2015 | 36 | 0.270 |
Why?
|
| Process Assessment (Health Care) | 2 | 2017 | 27 | 0.270 |
Why?
|
| Coronary Angiography | 3 | 2014 | 22 | 0.270 |
Why?
|
| Albuminuria | 3 | 2021 | 39 | 0.270 |
Why?
|
| Lower Extremity | 2 | 2015 | 13 | 0.260 |
Why?
|
| Life Style | 3 | 2022 | 329 | 0.260 |
Why?
|
| Hypolipidemic Agents | 2 | 2020 | 45 | 0.260 |
Why?
|
| Embolism | 3 | 2015 | 6 | 0.260 |
Why?
|
| Systole | 5 | 2016 | 22 | 0.260 |
Why?
|
| Thrombolytic Therapy | 4 | 2001 | 21 | 0.260 |
Why?
|
| Comparative Effectiveness Research | 3 | 2015 | 72 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2024 | 742 | 0.260 |
Why?
|
| Asthma | 3 | 2007 | 302 | 0.250 |
Why?
|
| Telemedicine | 2 | 2020 | 187 | 0.250 |
Why?
|
| Health Behavior | 4 | 2016 | 379 | 0.250 |
Why?
|
| Research | 4 | 2017 | 73 | 0.250 |
Why?
|
| Health Status Indicators | 4 | 2020 | 66 | 0.250 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2023 | 53 | 0.250 |
Why?
|
| Poverty | 2 | 2024 | 177 | 0.250 |
Why?
|
| Cerebral Hemorrhage | 3 | 2014 | 14 | 0.250 |
Why?
|
| Postoperative Complications | 3 | 2016 | 101 | 0.250 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2004 | 3 | 0.240 |
Why?
|
| Blood Glucose | 4 | 2016 | 344 | 0.240 |
Why?
|
| Insulin | 4 | 2015 | 208 | 0.240 |
Why?
|
| Patient Care Management | 1 | 2004 | 31 | 0.240 |
Why?
|
| Analysis of Variance | 5 | 2017 | 162 | 0.240 |
Why?
|
| Lung | 2 | 2018 | 46 | 0.240 |
Why?
|
| Specialization | 3 | 2001 | 23 | 0.240 |
Why?
|
| Medicine | 3 | 2001 | 23 | 0.240 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 2 | 2022 | 3 | 0.230 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2017 | 393 | 0.230 |
Why?
|
| Thiophenes | 2 | 2013 | 2 | 0.230 |
Why?
|
| Factor Xa | 2 | 2013 | 2 | 0.230 |
Why?
|
| Morpholines | 2 | 2013 | 3 | 0.230 |
Why?
|
| Cholesterol, HDL | 4 | 2023 | 80 | 0.230 |
Why?
|
| Thrombosis | 1 | 2023 | 11 | 0.230 |
Why?
|
| Acute Coronary Syndrome | 2 | 2016 | 17 | 0.230 |
Why?
|
| Protective Factors | 2 | 2020 | 32 | 0.230 |
Why?
|
| Genetic Variation | 3 | 2014 | 87 | 0.230 |
Why?
|
| Academies and Institutes | 1 | 2023 | 7 | 0.220 |
Why?
|
| Factor V | 1 | 2003 | 5 | 0.220 |
Why?
|
| Models, Statistical | 4 | 2012 | 184 | 0.220 |
Why?
|
| Aortic Valve | 1 | 2022 | 4 | 0.220 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2022 | 1 | 0.220 |
Why?
|
| Pre-Eclampsia | 1 | 2023 | 38 | 0.220 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2023 | 41 | 0.220 |
Why?
|
| Serine Endopeptidases | 1 | 2022 | 5 | 0.220 |
Why?
|
| Prosthesis Implantation | 3 | 2015 | 6 | 0.220 |
Why?
|
| Factor IX | 1 | 2022 | 3 | 0.220 |
Why?
|
| Lipocalin-2 | 3 | 2017 | 3 | 0.220 |
Why?
|
| Triglycerides | 2 | 2021 | 86 | 0.220 |
Why?
|
| Meals | 1 | 2022 | 7 | 0.220 |
Why?
|
| Terminology as Topic | 3 | 2010 | 21 | 0.220 |
Why?
|
| Retinal Vessels | 2 | 2020 | 4 | 0.210 |
Why?
|
| Lipids | 3 | 2019 | 77 | 0.210 |
Why?
|
| Observational Studies as Topic | 2 | 2020 | 49 | 0.210 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2022 | 4 | 0.210 |
Why?
|
| Emergency Medical Services | 2 | 2021 | 46 | 0.210 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2022 | 9 | 0.210 |
Why?
|
| Health Status | 5 | 2018 | 331 | 0.210 |
Why?
|
| Nephrosis, Lipoid | 1 | 2021 | 1 | 0.210 |
Why?
|
| Churg-Strauss Syndrome | 3 | 2007 | 3 | 0.200 |
Why?
|
| Mentoring | 1 | 2022 | 28 | 0.200 |
Why?
|
| Angioedema | 1 | 2021 | 8 | 0.200 |
Why?
|
| Antiviral Agents | 1 | 2022 | 96 | 0.200 |
Why?
|
| Risk Reduction Behavior | 2 | 2020 | 114 | 0.200 |
Why?
|
| Biopsy | 1 | 2021 | 73 | 0.200 |
Why?
|
| Calcium | 3 | 2012 | 34 | 0.200 |
Why?
|
| Animals | 5 | 2021 | 250 | 0.200 |
Why?
|
| Fibrinogen | 3 | 2017 | 13 | 0.200 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2021 | 1 | 0.200 |
Why?
|
| Chemokine CCL2 | 1 | 2021 | 1 | 0.200 |
Why?
|
| Kidney Tubules | 1 | 2021 | 1 | 0.190 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 316 | 0.190 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 22 | 0.190 |
Why?
|
| Asymptomatic Diseases | 3 | 2016 | 29 | 0.190 |
Why?
|
| Angina, Unstable | 4 | 2014 | 7 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2013 | 7 | 0.190 |
Why?
|
| Leukotriene Antagonists | 2 | 2007 | 8 | 0.190 |
Why?
|
| Ontario | 1 | 2020 | 15 | 0.190 |
Why?
|
| HIV Infections | 2 | 2022 | 682 | 0.190 |
Why?
|
| Jaw Diseases | 2 | 2011 | 11 | 0.190 |
Why?
|
| Osteonecrosis | 2 | 2011 | 12 | 0.190 |
Why?
|
| Hip Fractures | 2 | 2016 | 70 | 0.190 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 53 | 0.190 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 35 | 0.190 |
Why?
|
| Cognitive Dysfunction | 2 | 2024 | 46 | 0.190 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 2 | 2017 | 2 | 0.190 |
Why?
|
| Fatty Acid-Binding Proteins | 2 | 2017 | 2 | 0.190 |
Why?
|
| Arginine | 2 | 2010 | 12 | 0.180 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 33 | 0.180 |
Why?
|
| Europe | 4 | 2015 | 38 | 0.180 |
Why?
|
| Long Term Adverse Effects | 1 | 2020 | 3 | 0.180 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 56 | 0.180 |
Why?
|
| Pregnancy | 3 | 2023 | 1484 | 0.180 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2020 | 7 | 0.180 |
Why?
|
| Cigarette Smoking | 1 | 2020 | 4 | 0.180 |
Why?
|
| Physicians | 1 | 2021 | 143 | 0.180 |
Why?
|
| Diabetic Nephropathies | 3 | 2010 | 28 | 0.180 |
Why?
|
| Executive Function | 2 | 2017 | 21 | 0.180 |
Why?
|
| Vasodilation | 2 | 2011 | 8 | 0.180 |
Why?
|
| Pyrazoles | 1 | 2019 | 4 | 0.180 |
Why?
|
| Population Dynamics | 1 | 2019 | 6 | 0.180 |
Why?
|
| Pyridines | 2 | 2016 | 10 | 0.180 |
Why?
|
| Pyridones | 1 | 2019 | 7 | 0.180 |
Why?
|
| Ischemic Attack, Transient | 3 | 2014 | 28 | 0.180 |
Why?
|
| Gastrointestinal Diseases | 2 | 2018 | 28 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 129 | 0.170 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2016 | 4 | 0.170 |
Why?
|
| International Classification of Diseases | 2 | 2020 | 87 | 0.170 |
Why?
|
| Attitude to Health | 1 | 2020 | 179 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 3 | 2016 | 264 | 0.170 |
Why?
|
| Patient Participation | 1 | 2020 | 143 | 0.170 |
Why?
|
| Healthcare Disparities | 3 | 2017 | 205 | 0.170 |
Why?
|
| Health Care Costs | 4 | 2014 | 253 | 0.170 |
Why?
|
| Reoperation | 2 | 2016 | 30 | 0.160 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 57 | 0.160 |
Why?
|
| Withholding Treatment | 3 | 2020 | 26 | 0.160 |
Why?
|
| Smoking Cessation | 1 | 2020 | 198 | 0.160 |
Why?
|
| Genetic Loci | 2 | 2015 | 60 | 0.160 |
Why?
|
| Validation Studies as Topic | 1 | 2017 | 12 | 0.160 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 97 | 0.160 |
Why?
|
| Cardiologists | 1 | 2017 | 7 | 0.160 |
Why?
|
| Lipoprotein(a) | 1 | 2017 | 7 | 0.150 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2003 | 105 | 0.150 |
Why?
|
| Advisory Committees | 2 | 2009 | 111 | 0.150 |
Why?
|
| Acclimatization | 1 | 2017 | 1 | 0.150 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2017 | 2 | 0.150 |
Why?
|
| Ventilation | 1 | 2017 | 2 | 0.150 |
Why?
|
| Hypoxia | 1 | 2017 | 7 | 0.150 |
Why?
|
| Ibuprofen | 1 | 2017 | 9 | 0.150 |
Why?
|
| Patient Admission | 1 | 2018 | 72 | 0.150 |
Why?
|
| beta-Alanine | 3 | 2013 | 3 | 0.150 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2017 | 1 | 0.150 |
Why?
|
| Pacemaker, Artificial | 1 | 2017 | 2 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2012 | 205 | 0.150 |
Why?
|
| Benzimidazoles | 3 | 2013 | 6 | 0.150 |
Why?
|
| Epigenesis, Genetic | 2 | 2015 | 25 | 0.150 |
Why?
|
| Mice | 3 | 2021 | 66 | 0.150 |
Why?
|
| Ankle Brachial Index | 2 | 2021 | 8 | 0.150 |
Why?
|
| Acetylglucosaminidase | 1 | 2017 | 1 | 0.150 |
Why?
|
| Awareness | 1 | 2017 | 18 | 0.150 |
Why?
|
| Hypoglycemic Agents | 2 | 2012 | 289 | 0.150 |
Why?
|
| Urine Specimen Collection | 1 | 2016 | 1 | 0.150 |
Why?
|
| Urine | 1 | 2016 | 4 | 0.150 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 3 | 0.150 |
Why?
|
| Prosthesis Design | 1 | 2016 | 4 | 0.150 |
Why?
|
| Thiazoles | 1 | 2016 | 9 | 0.140 |
Why?
|
| Fee-for-Service Plans | 2 | 2014 | 28 | 0.140 |
Why?
|
| Drug Labeling | 1 | 2016 | 14 | 0.140 |
Why?
|
| Crotalid Venoms | 1 | 2016 | 1 | 0.140 |
Why?
|
| Atrial Appendage | 1 | 2016 | 1 | 0.140 |
Why?
|
| Health Policy | 2 | 2016 | 135 | 0.140 |
Why?
|
| Kidney Neoplasms | 2 | 2014 | 16 | 0.140 |
Why?
|
| Computer Simulation | 2 | 2016 | 84 | 0.140 |
Why?
|
| Up-Regulation | 1 | 2016 | 7 | 0.140 |
Why?
|
| Health Information Systems | 1 | 2016 | 4 | 0.140 |
Why?
|
| Hyponatremia | 1 | 2016 | 4 | 0.140 |
Why?
|
| Cytokines | 1 | 2016 | 27 | 0.140 |
Why?
|
| Heart Block | 1 | 2016 | 1 | 0.140 |
Why?
|
| Data Mining | 1 | 2016 | 21 | 0.140 |
Why?
|
| Thrombophlebitis | 1 | 2016 | 2 | 0.140 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 163 | 0.140 |
Why?
|
| Anesthesia, Conduction | 1 | 1996 | 1 | 0.140 |
Why?
|
| Sick Sinus Syndrome | 1 | 2015 | 1 | 0.140 |
Why?
|
| Anesthesia, General | 1 | 1996 | 3 | 0.140 |
Why?
|
| Hypoalbuminemia | 1 | 2015 | 1 | 0.140 |
Why?
|
| Blood Coagulation Tests | 1 | 2015 | 1 | 0.140 |
Why?
|
| Heart Defects, Congenital | 1 | 2016 | 37 | 0.140 |
Why?
|
| Patient Education as Topic | 2 | 2017 | 215 | 0.140 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2015 | 1 | 0.130 |
Why?
|
| Intermittent Claudication | 1 | 2015 | 2 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 8 | 0.130 |
Why?
|
| Ischemia | 1 | 2015 | 4 | 0.130 |
Why?
|
| Endovascular Procedures | 1 | 2015 | 6 | 0.130 |
Why?
|
| Recombinant Proteins | 4 | 2011 | 14 | 0.130 |
Why?
|
| Hypertriglyceridemia | 1 | 2015 | 13 | 0.130 |
Why?
|
| Body Size | 1 | 2015 | 31 | 0.130 |
Why?
|
| Community Networks | 2 | 2014 | 27 | 0.130 |
Why?
|
| Drug Prescriptions | 1 | 2016 | 157 | 0.130 |
Why?
|
| Incidental Findings | 3 | 2013 | 30 | 0.130 |
Why?
|
| Phosphates | 1 | 2015 | 3 | 0.130 |
Why?
|
| Chemokine CX3CL1 | 1 | 2015 | 1 | 0.130 |
Why?
|
| Brachial Artery | 2 | 2014 | 6 | 0.130 |
Why?
|
| Socioeconomic Factors | 5 | 2019 | 667 | 0.130 |
Why?
|
| Biological Assay | 1 | 2015 | 1 | 0.130 |
Why?
|
| Peer Group | 1 | 2015 | 50 | 0.130 |
Why?
|
| Healthy Volunteers | 1 | 2015 | 2 | 0.130 |
Why?
|
| Body Fat Distribution | 1 | 2015 | 5 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 2 | 2008 | 81 | 0.130 |
Why?
|
| Retreatment | 1 | 2014 | 10 | 0.130 |
Why?
|
| Adipose Tissue | 1 | 2015 | 59 | 0.130 |
Why?
|
| Acute-Phase Proteins | 1 | 2014 | 2 | 0.130 |
Why?
|
| Lipocalins | 1 | 2014 | 2 | 0.130 |
Why?
|
| Quality-Adjusted Life Years | 4 | 2019 | 42 | 0.130 |
Why?
|
| Ventricular Remodeling | 3 | 2023 | 6 | 0.130 |
Why?
|
| Epidemiologic Research Design | 1 | 2014 | 24 | 0.130 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2014 | 19 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 36 | 0.120 |
Why?
|
| Echocardiography, Stress | 1 | 2014 | 2 | 0.120 |
Why?
|
| Body Height | 1 | 2014 | 59 | 0.120 |
Why?
|
| Cardiac Catheterization | 1 | 2014 | 9 | 0.120 |
Why?
|
| Poisson Distribution | 3 | 2012 | 92 | 0.120 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2014 | 1 | 0.120 |
Why?
|
| Computer Communication Networks | 1 | 2014 | 18 | 0.120 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 3 | 0.120 |
Why?
|
| Regression Analysis | 5 | 2016 | 319 | 0.120 |
Why?
|
| Creatine | 1 | 2013 | 4 | 0.120 |
Why?
|
| Voluntary Health Agencies | 1 | 2013 | 1 | 0.120 |
Why?
|
| Centers for Disease Control and Prevention (U.S.) | 1 | 2013 | 33 | 0.120 |
Why?
|
| Gait | 1 | 2013 | 7 | 0.120 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2014 | 75 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2014 | 41 | 0.120 |
Why?
|
| Postural Balance | 1 | 2013 | 11 | 0.120 |
Why?
|
| Social Class | 3 | 2023 | 125 | 0.120 |
Why?
|
| Hospitalists | 1 | 2013 | 7 | 0.120 |
Why?
|
| Proteomics | 2 | 2023 | 7 | 0.120 |
Why?
|
| Gene Frequency | 3 | 2008 | 48 | 0.120 |
Why?
|
| Health Priorities | 1 | 2013 | 28 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 29 | 0.110 |
Why?
|
| Statistics as Topic | 4 | 2012 | 65 | 0.110 |
Why?
|
| Medicare Part C | 1 | 2013 | 22 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2013 | 73 | 0.110 |
Why?
|
| Age of Onset | 3 | 2008 | 82 | 0.110 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 17 | 0.110 |
Why?
|
| Digestive System Diseases | 1 | 2013 | 3 | 0.110 |
Why?
|
| Chemoprevention | 1 | 2012 | 12 | 0.110 |
Why?
|
| Cost of Illness | 2 | 2005 | 97 | 0.110 |
Why?
|
| Insulin Resistance | 2 | 2015 | 129 | 0.110 |
Why?
|
| Chest Pain | 4 | 2000 | 14 | 0.110 |
Why?
|
| Hypertensive Retinopathy | 1 | 2012 | 3 | 0.110 |
Why?
|
| Retinal Diseases | 1 | 2012 | 16 | 0.110 |
Why?
|
| Personnel Selection | 1 | 2012 | 6 | 0.110 |
Why?
|
| Marketing of Health Services | 1 | 2012 | 4 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 3 | 2017 | 9 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2017 | 26 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2004 | 138 | 0.110 |
Why?
|
| Nitroglycerin | 2 | 2011 | 6 | 0.100 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2011 | 9 | 0.100 |
Why?
|
| Vasodilator Agents | 2 | 2011 | 10 | 0.100 |
Why?
|
| Medicare Part D | 1 | 2012 | 22 | 0.100 |
Why?
|
| Adamantane | 1 | 2012 | 6 | 0.100 |
Why?
|
| Dipeptides | 1 | 2012 | 6 | 0.100 |
Why?
|
| Community-Based Participatory Research | 1 | 2012 | 63 | 0.100 |
Why?
|
| Mice, Knockout | 2 | 2011 | 15 | 0.100 |
Why?
|
| Ambulatory Care | 3 | 2014 | 274 | 0.100 |
Why?
|
| Central Nervous System Stimulants | 1 | 2011 | 29 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2012 | 71 | 0.100 |
Why?
|
| Cooperative Behavior | 2 | 2009 | 103 | 0.100 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2011 | 5 | 0.100 |
Why?
|
| Coronary Circulation | 1 | 2011 | 4 | 0.100 |
Why?
|
| Blood Flow Velocity | 2 | 2009 | 4 | 0.100 |
Why?
|
| Pulse | 2 | 2009 | 7 | 0.100 |
Why?
|
| Tibial Arteries | 1 | 2011 | 5 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 228 | 0.100 |
Why?
|
| Dental Care | 1 | 2011 | 15 | 0.100 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2011 | 34 | 0.100 |
Why?
|
| Models, Biological | 3 | 2016 | 32 | 0.100 |
Why?
|
| Tryptophan | 1 | 2010 | 3 | 0.100 |
Why?
|
| Kinesin | 1 | 2010 | 3 | 0.100 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 70 | 0.100 |
Why?
|
| Time | 1 | 2010 | 20 | 0.090 |
Why?
|
| Health Promotion | 1 | 2013 | 295 | 0.090 |
Why?
|
| Markov Chains | 3 | 2016 | 26 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2010 | 127 | 0.090 |
Why?
|
| Postmenopause | 2 | 2001 | 266 | 0.090 |
Why?
|
| Interviews as Topic | 1 | 2011 | 327 | 0.090 |
Why?
|
| Pharmacogenetics | 2 | 2008 | 16 | 0.090 |
Why?
|
| Vascular Resistance | 1 | 2009 | 1 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 103 | 0.090 |
Why?
|
| Aorta | 1 | 2009 | 5 | 0.090 |
Why?
|
| Blood Coagulation | 1 | 2009 | 2 | 0.090 |
Why?
|
| Intensive Care Units | 2 | 2009 | 103 | 0.090 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 3 | 0.090 |
Why?
|
| Nephrectomy | 1 | 2009 | 6 | 0.090 |
Why?
|
| Research Support as Topic | 1 | 2009 | 23 | 0.090 |
Why?
|
| Confounding Factors (Epidemiology) | 3 | 2012 | 97 | 0.090 |
Why?
|
| Dialysis | 1 | 2009 | 1 | 0.090 |
Why?
|
| Activities of Daily Living | 2 | 2008 | 92 | 0.090 |
Why?
|
| Anticholesteremic Agents | 1 | 2009 | 14 | 0.090 |
Why?
|
| Depression | 1 | 2014 | 512 | 0.090 |
Why?
|
| Evaluation Studies as Topic | 1 | 2009 | 33 | 0.090 |
Why?
|
| Gemfibrozil | 1 | 2009 | 5 | 0.090 |
Why?
|
| Rivaroxaban | 2 | 2023 | 7 | 0.080 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2009 | 24 | 0.080 |
Why?
|
| Bone Density Conservation Agents | 1 | 2009 | 55 | 0.080 |
Why?
|
| Linear Models | 3 | 2017 | 240 | 0.080 |
Why?
|
| Infant, Newborn | 1 | 2011 | 852 | 0.080 |
Why?
|
| Needs Assessment | 2 | 2016 | 73 | 0.080 |
Why?
|
| Communicable Disease Control | 1 | 2008 | 19 | 0.080 |
Why?
|
| Glycated Hemoglobin A | 4 | 2016 | 231 | 0.080 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2008 | 3 | 0.080 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2008 | 4 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2008 | 13 | 0.080 |
Why?
|
| Diabetes Complications | 3 | 2010 | 120 | 0.080 |
Why?
|
| Antifibrinolytic Agents | 2 | 2005 | 3 | 0.080 |
Why?
|
| Risk Adjustment | 1 | 2008 | 34 | 0.080 |
Why?
|
| Mental Health | 1 | 2010 | 166 | 0.080 |
Why?
|
| Health Surveys | 3 | 2017 | 266 | 0.080 |
Why?
|
| Program Development | 1 | 2008 | 78 | 0.080 |
Why?
|
| Endpoint Determination | 3 | 2012 | 10 | 0.080 |
Why?
|
| Colorado | 3 | 2015 | 207 | 0.080 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2007 | 3 | 0.080 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 3 | 0.080 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 4 | 0.080 |
Why?
|
| Myocardial Ischemia | 2 | 2013 | 24 | 0.080 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 4 | 0.080 |
Why?
|
| Health Services Research | 2 | 2017 | 271 | 0.080 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2007 | 7 | 0.080 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2007 | 4 | 0.080 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2007 | 4 | 0.080 |
Why?
|
| Glycemic Index | 1 | 2007 | 21 | 0.080 |
Why?
|
| Arteries | 1 | 2007 | 8 | 0.080 |
Why?
|
| Chemokines | 1 | 2007 | 8 | 0.080 |
Why?
|
| Multiphasic Screening | 1 | 2007 | 9 | 0.080 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2007 | 6 | 0.080 |
Why?
|
| Anti-HIV Agents | 1 | 2009 | 152 | 0.080 |
Why?
|
| Aluminum | 1 | 2007 | 14 | 0.080 |
Why?
|
| Molecular Epidemiology | 2 | 2008 | 44 | 0.080 |
Why?
|
| Epoetin Alfa | 1 | 2007 | 1 | 0.070 |
Why?
|
| Photography | 2 | 2020 | 9 | 0.070 |
Why?
|
| Medical Records | 4 | 2016 | 108 | 0.070 |
Why?
|
| Urinalysis | 2 | 2017 | 9 | 0.070 |
Why?
|
| Abdominal Fat | 1 | 2006 | 15 | 0.070 |
Why?
|
| Leptin | 1 | 2006 | 30 | 0.070 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2017 | 11 | 0.070 |
Why?
|
| Memory | 2 | 2017 | 12 | 0.070 |
Why?
|
| Drug Utilization | 2 | 2004 | 134 | 0.070 |
Why?
|
| Equipment Design | 2 | 2017 | 9 | 0.070 |
Why?
|
| Neuropsychological Tests | 2 | 2017 | 37 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2005 | 7 | 0.070 |
Why?
|
| Databases as Topic | 4 | 2009 | 20 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2005 | 16 | 0.070 |
Why?
|
| Oceanic Ancestry Group | 1 | 2005 | 34 | 0.070 |
Why?
|
| Waist-Hip Ratio | 2 | 2015 | 23 | 0.070 |
Why?
|
| Mass Screening | 1 | 2011 | 678 | 0.070 |
Why?
|
| Adipogenesis | 2 | 2015 | 3 | 0.060 |
Why?
|
| Global Health | 2 | 2016 | 29 | 0.060 |
Why?
|
| Hypothyroidism | 1 | 2005 | 8 | 0.060 |
Why?
|
| Medical Record Linkage | 2 | 2016 | 43 | 0.060 |
Why?
|
| Rats | 2 | 2017 | 28 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2015 | 7 | 0.060 |
Why?
|
| Managed Care Programs | 2 | 2004 | 356 | 0.060 |
Why?
|
| Macrolides | 1 | 2004 | 7 | 0.060 |
Why?
|
| Drug Interactions | 2 | 2017 | 21 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2019 | 33 | 0.060 |
Why?
|
| United States Food and Drug Administration | 2 | 2016 | 34 | 0.060 |
Why?
|
| ROC Curve | 2 | 2019 | 79 | 0.060 |
Why?
|
| Language | 2 | 2016 | 52 | 0.060 |
Why?
|
| Breast Diseases | 1 | 2004 | 17 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 19 | 0.060 |
Why?
|
| Calcitonin | 1 | 2003 | 1 | 0.060 |
Why?
|
| Breast | 1 | 2004 | 85 | 0.060 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2003 | 42 | 0.060 |
Why?
|
| Vaccination | 1 | 2008 | 664 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2022 | 3 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 6 | 0.050 |
Why?
|
| Models, Cardiovascular | 2 | 2013 | 4 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 12 | 0.050 |
Why?
|
| Fractures, Bone | 1 | 2003 | 91 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2023 | 53 | 0.050 |
Why?
|
| Deoxycholic Acid | 1 | 2022 | 1 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 40 | 0.050 |
Why?
|
| Sample Size | 2 | 2012 | 29 | 0.050 |
Why?
|
| Nutritive Value | 1 | 2022 | 11 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2022 | 176 | 0.050 |
Why?
|
| Observer Variation | 3 | 2010 | 39 | 0.050 |
Why?
|
| Brain | 1 | 2022 | 45 | 0.050 |
Why?
|
| Attitude | 1 | 2022 | 34 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2012 | 116 | 0.050 |
Why?
|
| Patient Freedom of Choice Laws | 1 | 2001 | 1 | 0.050 |
Why?
|
| Pharmacoepidemiology | 1 | 2001 | 22 | 0.050 |
Why?
|
| Energy Metabolism | 2 | 2015 | 47 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2012 | 235 | 0.050 |
Why?
|
| Cresols | 1 | 2021 | 1 | 0.050 |
Why?
|
| Glycine | 1 | 2021 | 1 | 0.050 |
Why?
|
| Indican | 1 | 2021 | 1 | 0.050 |
Why?
|
| Kynurenic Acid | 1 | 2021 | 1 | 0.050 |
Why?
|
| Pyridoxic Acid | 1 | 2021 | 1 | 0.050 |
Why?
|
| Ribonucleosides | 1 | 2021 | 1 | 0.050 |
Why?
|
| Sulfuric Acid Esters | 1 | 2021 | 1 | 0.050 |
Why?
|
| Organic Anion Transporters | 1 | 2021 | 1 | 0.050 |
Why?
|
| Xanthines | 1 | 2021 | 6 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2021 | 6 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 6 | 0.050 |
Why?
|
| Health Services Misuse | 1 | 2001 | 14 | 0.050 |
Why?
|
| Health Services for the Aged | 1 | 2001 | 15 | 0.050 |
Why?
|
| Africa | 2 | 2011 | 5 | 0.050 |
Why?
|
| Galectins | 1 | 2020 | 1 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2020 | 3 | 0.050 |
Why?
|
| Heart Valves | 1 | 2000 | 4 | 0.050 |
Why?
|
| Transferrins | 1 | 2020 | 4 | 0.050 |
Why?
|
| Transferrin | 1 | 2020 | 5 | 0.050 |
Why?
|
| Smoking | 3 | 2010 | 465 | 0.050 |
Why?
|
| Ferritins | 1 | 2020 | 10 | 0.050 |
Why?
|
| Contraindications | 1 | 1999 | 16 | 0.050 |
Why?
|
| Hematologic Tests | 1 | 2019 | 4 | 0.040 |
Why?
|
| Internal Medicine | 1 | 2000 | 28 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2001 | 178 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 16 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2019 | 32 | 0.040 |
Why?
|
| Cardiology Service, Hospital | 1 | 1999 | 2 | 0.040 |
Why?
|
| Family Practice | 1 | 2000 | 58 | 0.040 |
Why?
|
| Death | 1 | 2019 | 10 | 0.040 |
Why?
|
| Diagnosis-Related Groups | 1 | 1999 | 31 | 0.040 |
Why?
|
| Diet | 1 | 2022 | 359 | 0.040 |
Why?
|
| Reference Values | 2 | 2011 | 86 | 0.040 |
Why?
|
| Asia | 2 | 2011 | 15 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2020 | 248 | 0.040 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2017 | 1 | 0.040 |
Why?
|
| Respiratory Center | 1 | 2017 | 1 | 0.040 |
Why?
|
| Solitary Nucleus | 1 | 2017 | 1 | 0.040 |
Why?
|
| Neuroglia | 1 | 2017 | 3 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2017 | 7 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 3 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 3 | 0.040 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2017 | 2 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2017 | 10 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2017 | 3 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 3 | 0.040 |
Why?
|
| Comprehension | 1 | 2017 | 21 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2016 | 1 | 0.040 |
Why?
|
| Hypercholesterolemia | 2 | 2010 | 33 | 0.040 |
Why?
|
| Organ Size | 1 | 2016 | 16 | 0.040 |
Why?
|
| Diastole | 1 | 2016 | 5 | 0.040 |
Why?
|
| Myocardial Reperfusion | 2 | 2007 | 2 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2008 | 10 | 0.040 |
Why?
|
| Iothalamic Acid | 1 | 2016 | 2 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2016 | 42 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 2016 | 2 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2016 | 5 | 0.040 |
Why?
|
| Septal Occluder Device | 1 | 2016 | 1 | 0.040 |
Why?
|
| Decision Trees | 1 | 2016 | 20 | 0.040 |
Why?
|
| Goals | 1 | 2016 | 29 | 0.040 |
Why?
|
| Data Curation | 1 | 2016 | 1 | 0.040 |
Why?
|
| Sweden | 1 | 2016 | 18 | 0.030 |
Why?
|
| Orientation | 1 | 2016 | 1 | 0.030 |
Why?
|
| Trail Making Test | 1 | 2016 | 2 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2016 | 4 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2016 | 16 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 1996 | 5 | 0.030 |
Why?
|
| Caregivers | 1 | 2017 | 125 | 0.030 |
Why?
|
| Attention | 1 | 2016 | 10 | 0.030 |
Why?
|
| Cuba | 1 | 2015 | 1 | 0.030 |
Why?
|
| Dominican Republic | 1 | 2015 | 1 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2015 | 5 | 0.030 |
Why?
|
| South America | 1 | 2015 | 5 | 0.030 |
Why?
|
| Diagnosis | 1 | 1995 | 5 | 0.030 |
Why?
|
| Central America | 1 | 2015 | 6 | 0.030 |
Why?
|
| Cell Line | 2 | 2012 | 9 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 1 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 9 | 0.030 |
Why?
|
| Mexico | 1 | 2015 | 21 | 0.030 |
Why?
|
| Medical Informatics | 1 | 2016 | 43 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2015 | 23 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2015 | 22 | 0.030 |
Why?
|
| Amputation | 1 | 2015 | 11 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 7 | 0.030 |
Why?
|
| Diabetic Angiopathies | 1 | 2015 | 35 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2015 | 65 | 0.030 |
Why?
|
| Myocardial Contraction | 1 | 2015 | 1 | 0.030 |
Why?
|
| Retinal Artery | 1 | 2015 | 2 | 0.030 |
Why?
|
| Retinal Vein | 1 | 2015 | 2 | 0.030 |
Why?
|
| Angiography | 1 | 2015 | 11 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2015 | 8 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2015 | 2 | 0.030 |
Why?
|
| Synapses | 1 | 2015 | 2 | 0.030 |
Why?
|
| Adipocytes | 1 | 2015 | 4 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 6 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2015 | 3 | 0.030 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 56 | 0.030 |
Why?
|
| Psychotic Disorders | 1 | 2015 | 47 | 0.030 |
Why?
|
| Genome, Human | 1 | 2015 | 41 | 0.030 |
Why?
|
| Anxiety Disorders | 1 | 2015 | 91 | 0.030 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2014 | 7 | 0.030 |
Why?
|
| Clinical Competence | 1 | 1995 | 109 | 0.030 |
Why?
|
| Genetics, Population | 1 | 2014 | 8 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 24 | 0.030 |
Why?
|
| Radial Artery | 1 | 2014 | 2 | 0.030 |
Why?
|
| Femoral Artery | 1 | 2014 | 4 | 0.030 |
Why?
|
| San Francisco | 2 | 2008 | 67 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 1 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2013 | 4 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2014 | 55 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2013 | 3 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2013 | 3 | 0.030 |
Why?
|
| Capitation Fee | 1 | 2013 | 12 | 0.030 |
Why?
|
| Fatigue | 1 | 2013 | 35 | 0.030 |
Why?
|
| Geography | 1 | 2013 | 38 | 0.030 |
Why?
|
| Reimbursement, Incentive | 1 | 2013 | 30 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2015 | 233 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 2013 | 35 | 0.030 |
Why?
|
| Peritoneal Dialysis | 1 | 2013 | 7 | 0.030 |
Why?
|
| History, Ancient | 1 | 2013 | 2 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2013 | 36 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2012 | 9 | 0.030 |
Why?
|
| Protein Precursors | 1 | 2012 | 5 | 0.030 |
Why?
|
| Multilingualism | 1 | 2012 | 9 | 0.030 |
Why?
|
| Chicago | 1 | 2012 | 27 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2012 | 160 | 0.030 |
Why?
|
| Amiodarone | 1 | 2012 | 2 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2012 | 16 | 0.030 |
Why?
|
| Calcium Channel Blockers | 1 | 2012 | 16 | 0.030 |
Why?
|
| Informed Consent | 1 | 2012 | 21 | 0.030 |
Why?
|
| Drug Approval | 1 | 2012 | 14 | 0.030 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2012 | 8 | 0.030 |
Why?
|
| Glucuronidase | 1 | 2011 | 1 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2011 | 1 | 0.030 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2011 | 1 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2011 | 1 | 0.030 |
Why?
|
| Philippines | 1 | 2011 | 22 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 17 | 0.030 |
Why?
|
| Drug Utilization Review | 2 | 2003 | 28 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2012 | 51 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2011 | 30 | 0.030 |
Why?
|
| Nitric Oxide Donors | 1 | 2011 | 3 | 0.030 |
Why?
|
| Alcoholism | 1 | 2015 | 346 | 0.020 |
Why?
|
| Decision Making | 1 | 2013 | 204 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2011 | 5 | 0.020 |
Why?
|
| Critical Illness | 1 | 2012 | 53 | 0.020 |
Why?
|
| Critical Care | 1 | 2012 | 72 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 20 | 0.020 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2012 | 113 | 0.020 |
Why?
|
| Weight Loss | 1 | 2013 | 296 | 0.020 |
Why?
|
| Proviruses | 1 | 1990 | 1 | 0.020 |
Why?
|
| Internationality | 1 | 2010 | 12 | 0.020 |
Why?
|
| Virus Replication | 1 | 1990 | 12 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 9 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2011 | 126 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2010 | 9 | 0.020 |
Why?
|
| HIV-1 | 1 | 1990 | 72 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2011 | 136 | 0.020 |
Why?
|
| Medication Therapy Management | 1 | 2010 | 6 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 70 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2009 | 1 | 0.020 |
Why?
|
| Prescriptions | 1 | 2010 | 28 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2009 | 23 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 50 | 0.020 |
Why?
|
| Emigration and Immigration | 1 | 2009 | 14 | 0.020 |
Why?
|
| Etidronic Acid | 1 | 2009 | 4 | 0.020 |
Why?
|
| Tooth Extraction | 1 | 2009 | 6 | 0.020 |
Why?
|
| Self Report | 1 | 2011 | 252 | 0.020 |
Why?
|
| Alendronate | 1 | 2009 | 16 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 97 | 0.020 |
Why?
|
| Psychometrics | 1 | 2010 | 120 | 0.020 |
Why?
|
| Educational Status | 1 | 2009 | 205 | 0.020 |
Why?
|
| Emigrants and Immigrants | 1 | 2009 | 31 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2008 | 4 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 10 | 0.020 |
Why?
|
| 5-Lipoxygenase-Activating Proteins | 1 | 2008 | 4 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 15 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2008 | 38 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 11 | 0.020 |
Why?
|
| Public Health | 1 | 2009 | 80 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Alleles | 1 | 2008 | 93 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2000 | 58 | 0.020 |
Why?
|
| Mutagenesis | 1 | 2007 | 4 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 9 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 46 | 0.020 |
Why?
|
| Manometry | 1 | 2007 | 1 | 0.020 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2007 | 23 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 5 | 0.020 |
Why?
|
| Sulfonylurea Compounds | 1 | 2007 | 28 | 0.020 |
Why?
|
| Thiazolidinediones | 1 | 2007 | 54 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2007 | 40 | 0.020 |
Why?
|
| Metformin | 1 | 2007 | 60 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2007 | 60 | 0.020 |
Why?
|
| Leisure Activities | 1 | 2006 | 33 | 0.020 |
Why?
|
| Pacific Islands | 1 | 2005 | 5 | 0.020 |
Why?
|
| Phosphorus | 1 | 2005 | 5 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2005 | 30 | 0.020 |
Why?
|
| Heparin | 1 | 2004 | 9 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 257 | 0.020 |
Why?
|
| Radiography | 1 | 2004 | 39 | 0.020 |
Why?
|
| Wrist Injuries | 1 | 2003 | 1 | 0.010 |
Why?
|
| Spinal Fractures | 1 | 2003 | 12 | 0.010 |
Why?
|
| Women's Health | 1 | 2004 | 208 | 0.010 |
Why?
|
| Vitamin K 1 | 1 | 2001 | 1 | 0.010 |
Why?
|
| Half-Life | 1 | 2001 | 5 | 0.010 |
Why?
|
| Economics, Pharmaceutical | 1 | 2001 | 3 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2001 | 51 | 0.010 |
Why?
|
| Syndrome | 1 | 2001 | 31 | 0.010 |
Why?
|
| Hospitals, Community | 1 | 2001 | 23 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2001 | 24 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2000 | 4 | 0.010 |
Why?
|
| Health Education | 1 | 2001 | 118 | 0.010 |
Why?
|
| Troponin | 1 | 2000 | 9 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 2000 | 35 | 0.010 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2001 | 118 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2001 | 233 | 0.010 |
Why?
|
| Medicare Part A | 1 | 1999 | 3 | 0.010 |
Why?
|
| Medical Audit | 1 | 1999 | 40 | 0.010 |
Why?
|
| Hospitals, University | 1 | 1999 | 20 | 0.010 |
Why?
|
| Probability | 1 | 1999 | 86 | 0.010 |
Why?
|
| Hospitals, General | 1 | 1995 | 4 | 0.010 |
Why?
|
| Schools, Medical | 1 | 1995 | 17 | 0.010 |
Why?
|
| Massachusetts | 1 | 1995 | 100 | 0.010 |
Why?
|
| Globins | 1 | 1990 | 1 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1990 | 1 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 3 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1990 | 3 | 0.010 |
Why?
|
| Kinetics | 1 | 1990 | 11 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1990 | 11 | 0.010 |
Why?
|
| Base Sequence | 1 | 1990 | 20 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1990 | 18 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1990 | 17 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1990 | 7 | 0.010 |
Why?
|
| Leukocytes | 1 | 1990 | 9 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1990 | 53 | 0.010 |
Why?
|